| Serial Number | 98555936 |
| Word Mark | EXENDUBEK |
| Filing Date | Friday, May 17, 2024 |
| Status | 645 - FINAL REFUSAL - MAILED |
| Status Date | Thursday, March 13, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
| Goods and Services | Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressant preparations, pharmaceutical antibodies for medical use, and immunotherapy preparations for the treatment of cancer; cytokine inhibitory drugs being pharmaceutical preparations for the treatment of cancer; anticoagulants; Pharmaceutical preparations for human use that modulate the immune system for the treatment of immune-system related diseases and disorders; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy for the treatment of cancer; Pharmaceutical and biological preparations for human use, namely, stem cells for medical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; Pharmaceutical preparations for human use for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for human use for the treatment of cancer and solid tumors; diagnostic radiopharmaceutical preparations for human use; diagnostic preparations for human use for medical purposes; radiopharmaceutical preparations for human use in the nature of imaging and detection agents for diagnosing and monitoring cancer; biological preparations for human use in the nature of radio-isotope markers for therapeutic or diagnostic use; Pharmaceutical preparations for human use for the treatment of cystic fibrosis. |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, May 17, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Celgene Corporation |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Princeton, NJ 08543 |
| Event Date | Event Description |
| Friday, May 17, 2024 | NEW APPLICATION ENTERED |
| Wednesday, November 20, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, November 21, 2024 | ASSIGNED TO EXAMINER |
| Friday, November 22, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, November 22, 2024 | NON-FINAL ACTION WRITTEN |
| Friday, November 22, 2024 | NON-FINAL ACTION E-MAILED |
| Monday, February 24, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, February 24, 2025 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, February 24, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, March 13, 2025 | FINAL REFUSAL E-MAILED |
| Thursday, March 13, 2025 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Thursday, March 13, 2025 | FINAL REFUSAL WRITTEN |